Nonpeptide alpha(v)beta3 antagonists: identification of potent, chain-shortened 7-oxo RGD mimetics.
Potent, novel 7-oxo alpha(v)beta3 antagonists have been prepared. These antagonists offer decreased plasma protein binding and excellent pharmacokinetic profiles.
Zartman
Amy E
AE
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. amy_zartman@merck.com
Duong
Le T
LT
Fernandez-Metzler
Carmen
C
Hartman
George D
GD
Leu
Chih-Tai
CT
Prueksaritanont
Thomayant
T
Rodan
Gideon A
GA
Rodan
Sevgi B
SB
Duggan
Mark E
ME
Meissner
Robert S
RS
D000818:Animals; D004285:Dogs; D006574:Heterocyclic Compounds, 2-Ring / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D039302:Integrin alphaVbeta3 / Q000037:antagonists & inhibitors*; D008956:Models, Chemical; D015394:Molecular Structure; D009842:Oligopeptides; D010024:Osteoporosis / Q000188:drug therapy; D013329:Structure-Activity Relationship
D006574:Heterocyclic Compounds, 2-Ring; D039302:Integrin alphaVbeta3; D009842:Oligopeptides; C047981:arginyl-glycyl-aspartic acid